New Zealand markets closed

Aprea Therapeutics, Inc. (APRE)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
4.0700-0.0200 (-0.49%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 22.10M
Enterprise value -6.69M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.76
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.35

Trading information

Stock price history

Beta (5Y monthly) 1.98
52-week change 325.69%
S&P500 52-week change 322.55%
52-week high 38.8470
52-week low 32.7800
50-day moving average 34.9025
200-day moving average 35.0722

Share statistics

Avg vol (3-month) 39.56k
Avg vol (10-day) 316k
Shares outstanding 55.43M
Implied shares outstanding 65.43M
Float 84.01M
% held by insiders 111.27%
% held by institutions 139.95%
Shares short (14 Jun 2024) 419.64k
Short ratio (14 Jun 2024) 42.17
Short % of float (14 Jun 2024) 40.49%
Short % of shares outstanding (14 Jun 2024) 40.36%
Shares short (prior month 15 May 2024) 432.35k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 313 Feb 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-827.62%

Management effectiveness

Return on assets (ttm)-26.83%
Return on equity (ttm)-43.83%

Income statement

Revenue (ttm)963.8k
Revenue per share (ttm)0.25
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -13.99M
Net income avi to common (ttm)-12.72M
Diluted EPS (ttm)-3.2800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)32.37M
Total cash per share (mrq)5.96
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)11.15
Book value per share (mrq)5.33

Cash flow statement

Operating cash flow (ttm)-13.13M
Levered free cash flow (ttm)-9.26M